The Female Reproductive Tract Microbiome and Cancerogenesis: A Review Story of Bacteria, Hormones, and Disease

The microbiota is the complex community of microorganisms that populate a particular environment in the human body, whereas the microbiome is defined by the entire habitat—microorganisms and their environment. The most abundant and, therefore, the most studied microbiome is that of the gastrointestinal tract. However, the microbiome of the female reproductive tract is an interesting research avenue, and this article explores its role in disease development. The vagina is the reproductive organ that hosts the largest number of bacteria, with a healthy profile represented mainly by Lactobacillus spp. On the other hand, the female upper reproductive tract (uterus, Fallopian tubes, ovaries) contains only a very small number of bacteria. Previously considered sterile, recent studies have shown the presence of a small microbiota here, but there are still debates on whether this is a physiologic or pathologic occurrence. Of particular note is that estrogen levels significantly influence the composition of the microbiota of the female reproductive tract. More and more studies show a link between the microbiome of the female reproductive tract and the development of gynecological cancers. This article reviews some of these findings.

[1]  Xin Li,et al.  Roles of vaginal flora in human papillomavirus infection, virus persistence and clearance , 2023, Frontiers in Cellular and Infection Microbiology.

[2]  Gun-Hee Kim,et al.  Anti-Tumor Effects of Heat-Killed L. reuteri MG5346 and L. casei MG4584 against Human Colorectal Carcinoma through Caspase-9-Dependent Apoptosis in Xenograft Model , 2022, Microorganisms.

[3]  C. Allaire,et al.  Intricate Connections between the Microbiota and Endometriosis , 2021, International journal of molecular sciences.

[4]  P. Cassoni,et al.  Gut Microbiota and Gynecological Cancers: A Summary of Pathogenetic Mechanisms and Future Directions. , 2021, ACS infectious diseases.

[5]  J. Hasty,et al.  The microbiome and human cancer , 2021, Science.

[6]  J. Gonzalez-Bosquet,et al.  Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome , 2021, Cancers.

[7]  Huanrong Li,et al.  The Interaction Between Microorganisms, Metabolites, and Immune System in the Female Genital Tract Microenvironment , 2020, Frontiers in Cellular and Infection Microbiology.

[8]  Li Tang,et al.  Dysbiosis of the endometrial microbiota and its association with inflammatory cytokines in endometrial cancer , 2020, International journal of cancer.

[9]  Xiaofeng Mu,et al.  Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection. , 2020, Microbial pathogenesis.

[10]  V. Bae-Jump,et al.  Diet and gut microbiome interactions in gynecologic cancer. , 2020, Gynecologic oncology.

[11]  Jan Claesen,et al.  Disruption of the gut microbiota attenuates epithelial ovarian cancer sensitivity to cisplatin therapy , 2020, bioRxiv.

[12]  S. Chilakapati,et al.  Microbiome and cancer immunotherapy. , 2020, Current opinion in biotechnology.

[13]  Jingbo Peng,et al.  Vaginal microbiomes and ovarian cancer: a review. , 2020, American journal of cancer research.

[14]  Rob Knight,et al.  Microbiome analyses of blood and tissues suggest cancer diagnostic approach , 2020, Nature.

[15]  Z. Ilhan,et al.  The microbiome and gynaecological cancer development, prevention and therapy , 2020, Nature Reviews Urology.

[16]  K. Konstantinidis,et al.  Comparison of vaginal microbiota in gynecologic cancer patients pre‐ and post‐radiation therapy and healthy women , 2019, Cancer medicine.

[17]  L. Engstrand,et al.  The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta‐analysis , 2019, BJOG : an international journal of obstetrics and gynaecology.

[18]  M. Momeny,et al.  Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid) , 2019, Cancer Chemotherapy and Pharmacology.

[19]  R. Pezo,et al.  Untapped “-omics”: the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment , 2019, Breast Cancer Research and Treatment.

[20]  G. Bonaccorsi,et al.  Atopobium vaginae And Porphyromonas somerae Induce Proinflammatory Cytokines Expression In Endometrial Cells: A Possible Implication For Endometrial Cancer? , 2019, Cancer management and research.

[21]  Hao Xu,et al.  The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice. , 2019, Life sciences.

[22]  A. Ryan,et al.  Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. , 2019, The Lancet. Oncology.

[23]  Yuli Chen,et al.  Intestinal dysbiosis promotes epithelial-mesenchymal transition by activating tumor-associated macrophages in ovarian cancer , 2019, Pathogens and disease.

[24]  Guoxing Fu,et al.  The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ , 2019, bioRxiv.

[25]  S. Fernando,et al.  Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions , 2019, mBio.

[26]  Junbo Hu,et al.  The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients , 2019, Scientific Reports.

[27]  A. Mitra,et al.  Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study , 2019, BMC Women's Health.

[28]  M. Torcia Interplay among Vaginal Microbiome, Immune Response and Sexually Transmitted Viral Infections , 2019, International journal of molecular sciences.

[29]  V. Azevedo,et al.  Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP , 2018, Scientific Reports.

[30]  V. Azevedo,et al.  Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP , 2018, Scientific Reports.

[31]  C. A. Speck-Hernandez,et al.  Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner. , 2018, Cancer research.

[32]  A. Mariani,et al.  Case for a role of the microbiome in gynecologic cancers: Clinician's perspective , 2018, The journal of obstetrics and gynaecology research.

[33]  C. Bolego,et al.  Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment , 2018, Biochemical pharmacology.

[34]  R. Montironi,et al.  Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. , 2018, European urology.

[35]  Z. Ilhan,et al.  Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics. , 2018, Maturitas.

[36]  Chang H. Kim Immune regulation by microbiome metabolites , 2018, Immunology.

[37]  A. Watson,et al.  Could Fecal Transplantation Become Part of PD-1-Based Immunotherapy, Due to Effects of the Intestinal Microbiome? , 2018, Gastroenterology.

[38]  M. Yuan,et al.  Endometriosis induces gut microbiota alterations in mice , 2018, Human reproduction.

[39]  M. Herbst-Kralovetz,et al.  Uterine Microbiota: Residents, Tourists, or Invaders? , 2018, Front. Immunol..

[40]  Yulong Yin,et al.  Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism , 2018, Front. Cell. Infect. Microbiol..

[41]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[42]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[43]  A. Pierangeli,et al.  Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection , 2018, BMC Infectious Diseases.

[44]  Z. Kokot,et al.  Usefulness of Amino Acid Profiling in Ovarian Cancer Screening with Special Emphasis on Their Role in Cancerogenesis , 2017, International journal of molecular sciences.

[45]  T. Hasan,et al.  Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis , 2017, Molecular Cancer Therapeutics.

[46]  M. Bogdanov,et al.  Biogenesis, transport and remodeling of lysophospholipids in Gram-negative bacteria. , 2017, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[47]  M. Herbst-Kralovetz,et al.  Estrogen-gut microbiome axis: Physiological and clinical implications. , 2017, Maturitas.

[48]  D. Cavalieri,et al.  Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection , 2017, Scientific Reports.

[49]  G. Park,et al.  Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells. , 2017, Oncology reports.

[50]  K. Bernstein,et al.  Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. , 2017, Obstetrics and gynecology.

[51]  Zhi Wei,et al.  The ovarian cancer oncobiome , 2017, Oncotarget.

[52]  Ian D. Wilson,et al.  Gut microbiota modulation of chemotherapy efficacy and toxicity , 2017, Nature Reviews Gastroenterology &Hepatology.

[53]  Chen Hu,et al.  Salinomycin repressed the epithelial–mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt/β-catenin pathway , 2017, OncoTargets and therapy.

[54]  Junling Zhang,et al.  Faecal microbiota transplantation protects against radiation‐induced toxicity , 2017, EMBO molecular medicine.

[55]  A. Patterson,et al.  The aryl hydrocarbon receptor as a moderator of host-microbiota communication. , 2017, Current opinion in toxicology.

[56]  J. Venter,et al.  The Human Microbiome and Cancer , 2017, Cancer Prevention Research.

[57]  So-Jin Shin,et al.  Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell , 2016, Journal of gynecologic oncology.

[58]  L. Kiemeney,et al.  Systematic Reviews and Meta- and Pooled Analyses Pelvic In fl ammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies , 2016 .

[59]  S. Lynch,et al.  The Human Intestinal Microbiome in Health and Disease. , 2016, The New England journal of medicine.

[60]  R. Dunn,et al.  Lactobacilli Dominance and Vaginal pH: Why Is the Human Vaginal Microbiome Unique? , 2016, Front. Microbiol..

[61]  A. Mariani,et al.  Potential contribution of the uterine microbiome in the development of endometrial cancer , 2016, Genome Medicine.

[62]  I. Vergote,et al.  The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer. , 2016, Anticancer research.

[63]  M. Herbst-Kralovetz,et al.  Menopause and the vaginal microbiome. , 2016, Maturitas.

[64]  L. Forney,et al.  Unraveling the Dynamics of the Human Vaginal Microbiome , 2016, The Yale journal of biology and medicine.

[65]  J. Marrazzo,et al.  The Vaginal Microbiome: Current Understanding and Future Directions. , 2016, The Journal of infectious diseases.

[66]  So-Jin Shin,et al.  The effect of salinomycin on ovarian cancer stem-like cells , 2016, Obstetrics & gynecology science.

[67]  R. Xavier,et al.  CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands , 2016, Nature Medicine.

[68]  A. Burguete-García,et al.  Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study , 2016, PloS one.

[69]  T. Hope,et al.  Glycogen Levels in Undiluted Genital Fluid and Their Relationship to Vaginal pH, Estrogen, and Progesterone , 2016, PloS one.

[70]  F. Markowetz,et al.  Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. , 2016, Cancer research.

[71]  F. Tekşen,et al.  Apoptotic effects of salinomycin on human ovarian cancer cell line (OVCAR-3) , 2016, Tumor Biology.

[72]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[73]  J. K. Nicholson,et al.  Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity , 2015, Scientific Reports.

[74]  Jens Nielsen,et al.  The gut microbiota modulates host amino acid and glutathione metabolism in mice , 2015 .

[75]  X. Hua,et al.  Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. , 2015, Journal of the National Cancer Institute.

[76]  J. Ravel,et al.  The vocabulary of microbiome research: a proposal , 2015, Microbiome.

[77]  Wendy S. Garrett,et al.  Cancer and the microbiota , 2015, Science.

[78]  F. Sotgia,et al.  Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease , 2015, Oncotarget.

[79]  S. Badar,et al.  Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. , 2015, American journal of cancer research.

[80]  G. Rabinovich,et al.  Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. , 2015, Cancer cell.

[81]  G. Trinchieri,et al.  The role of the microbiota in inflammation, carcinogenesis, and cancer therapy , 2015, European journal of immunology.

[82]  G. Lou,et al.  Large‐scale profiling of metabolic dysregulation in ovarian cancer , 2014, International journal of cancer.

[83]  Sandhya Kortagere,et al.  Symbiotic Bacterial Metabolites Regulate Gastrointestinal Barrier Function via the Xenobiotic Sensor PXR and Toll‐like Receptor 4 , 2014, Immunity.

[84]  F. Benencia,et al.  Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies , 2014, Front. Immunol..

[85]  R. Schwabe,et al.  The Microbiome and Cancer , 2021, Gut Feelings.

[86]  A. De Luca,et al.  Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. , 2013, Immunity.

[87]  L. Forney,et al.  Influence of Vaginal Bacteria and d- and l-Lactic Acid Isomers on Vaginal Extracellular Matrix Metalloproteinase Inducer: Implications for Protection against Upper Genital Tract Infections , 2013, mBio.

[88]  So-Jin Shin,et al.  Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian cancer cells. , 2013, Cancer epidemiology.

[89]  Eun Jin Seo,et al.  TAZ Mediates Lysophosphatidic Acid-Induced Migration and Proliferation of Epithelial Ovarian Cancer Cells , 2013, Cellular Physiology and Biochemistry.

[90]  S. Badar,et al.  Minocycline Targets the NF-κB Nexus through Suppression of TGF-β1-TAK1-IκB Signaling in Ovarian Cancer , 2013, Molecular Cancer Research.

[91]  S. Kjaer,et al.  Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors , 2013, Cancer Causes & Control.

[92]  D. Morris,et al.  Minocycline Suppresses Interleukine-6, Its Receptor System and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of Ovarian Cancer Cells: In Vitro and In Vivo Studies , 2013, PloS one.

[93]  S. Badar,et al.  Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways. , 2013, Gynecologic oncology.

[94]  So-Jin Shin,et al.  Salinomycin induces apoptosis via death receptor-5 up-regulation in cisplatin-resistant ovarian cancer cells. , 2013, Anticancer research.

[95]  Chang-Yun Lin,et al.  The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma , 2013, Molecular oncology.

[96]  Tao Zhang,et al.  Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. , 2013, Journal of proteome research.

[97]  J. Goedert,et al.  Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study , 2012, Journal of Translational Medicine.

[98]  M. Kleerebezem,et al.  The microbiota and the gut-brain axis: insights from the temporal and spatial mucosal alterations during colonisation of the germfree mouse intestine. , 2012, Beneficial microbes.

[99]  K. Jeong,et al.  The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion , 2012, Oncogene.

[100]  H. Flint,et al.  Phylogenetic distribution of genes encoding β-glucuronidase activity in human colonic bacteria and the impact of diet on faecal glycosidase activities. , 2012, Environmental microbiology.

[101]  J. Qiao,et al.  Bacterial vaginosis is conducive to the persistence of HPV infection , 2012, International journal of STD & AIDS.

[102]  Tao Zhang,et al.  Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[103]  Katherine H. Huang,et al.  Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.

[104]  Zaid Abdo,et al.  Temporal Dynamics of the Human Vaginal Microbiota , 2012, Science Translational Medicine.

[105]  Ming-zhu Yin,et al.  Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform , 2012, Acta oncologica.

[106]  T. Dinan,et al.  An effective dietary method for chronic tryptophan depletion in two mouse strains illuminates a role for 5-HT in nesting behaviour , 2012, Neuropharmacology.

[107]  G. Senthilkumar,et al.  Viral and bacterial aetiologies of epithelial ovarian cancer , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[108]  J. Paavonen Chlamydia trachomatis infections of the female genital tract: State of the art , 2012, Annals of medicine.

[109]  Liang Zhou,et al.  The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. , 2012, Immunity.

[110]  H. Tilg,et al.  Too much fat for the gut's microbiota , 2012, Gut.

[111]  A. Stapleton,et al.  Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[112]  Joris Meys,et al.  Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis , 2011, BMC infectious diseases.

[113]  S. Shiboski,et al.  Phase 2a Study Assessing Colonization Efficiency, Safety, and Acceptability of Lactobacillus crispatus CTV-05 in Women With Bacterial Vaginosis , 2010, Sexually transmitted diseases.

[114]  Alexander G. Gray,et al.  Rapid Mass Spectrometric Metabolic Profiling of Blood Sera Detects Ovarian Cancer with High Accuracy , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[115]  T. Drewa,et al.  The influence of ciprofloxacin on hamster ovarian cancer cell line CHO AA8. , 2010, Acta poloniae pharmaceutica.

[116]  J. Doré,et al.  A metagenomic β-glucuronidase uncovers a core adaptive function of the human intestinal microbiome , 2010, Proceedings of the National Academy of Sciences.

[117]  Y. Ainmelk,et al.  Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes , 2010, Journal of ovarian research.

[118]  J. Hurst,et al.  Lysophosphatidic Acid Stimulates Cell Growth by Different Mechanisms in SKOV-3 and Caov-3 Ovarian Cancer Cells: Distinct Roles for Gi- and Rho-Dependent Pathways , 2009, Pharmacology.

[119]  H. Tilg,et al.  Obesity and the microbiota. , 2009, Gastroenterology.

[120]  S. Mazmanian,et al.  The gut microbiota shapes intestinal immune responses during health and disease , 2009, Nature Reviews Immunology.

[121]  W. R. Wikoff,et al.  Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites , 2009, Proceedings of the National Academy of Sciences.

[122]  A. Pierangeli,et al.  Human Papillomaviruses and genital co-infections in gynaecological outpatients , 2009, BMC infectious diseases.

[123]  Y. Taketani,et al.  Interleukin (IL)-17A stimulates IL-8 secretion, cyclooxygensase-2 expression, and cell proliferation of endometriotic stromal cells. , 2008, Endocrinology.

[124]  C. Rock,et al.  Membrane lipid homeostasis in bacteria , 2008, Nature Reviews Microbiology.

[125]  C. Czuprynski,et al.  The Aryl Hydrocarbon Receptor Is Required for Optimal Resistance to Listeria monocytogenes Infection in Mice1 , 2007, The Journal of Immunology.

[126]  G. Mills,et al.  Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. , 2007, International journal of oncology.

[127]  R. Chen,et al.  TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. , 2006, Cancer research.

[128]  G. Mills,et al.  Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene α in Ovarian Cancer , 2006 .

[129]  J. Papp,et al.  Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. , 2005, American journal of epidemiology.

[130]  S. Hillier,et al.  Colonization of the rectum by Lactobacillus species and decreased risk of bacterial vaginosis. , 2005, The Journal of infectious diseases.

[131]  Yan Xu,et al.  A novel laminin‐induced lysophosphatidic acid autocrine loop in the migration of ovarian cancer cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[132]  G. Wilbanks,et al.  IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy. , 1999, Gynecologic oncology.

[133]  G. Mills,et al.  Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[134]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[135]  B. Piura,et al.  Tumor necrosis factor-alpha and interleukin-6 are differently expressed by fresh human cancerous ovarian tissue and primary cell lines. , 1998, European cytokine network.

[136]  B. Piura,et al.  Distinct patterns of expression of interleukin-1 alpha and beta by normal and cancerous human ovarian tissues. , 1997, European cytokine network.

[137]  G. Mills,et al.  Lysophospholipids activate ovarian and breast cancer cells. , 1995, The Biochemical journal.

[138]  M. Yokoyama,et al.  Microbial metabolites of tryptophan in the intestinal tract with special reference to skatole. , 1979, The American journal of clinical nutrition.